Initial Results From A Phase 2, Open-label Extension Study To Evaluate The Long-term Safety And Efficacy Of The Anti-KIT Briquilimab Antibody In Adults With Chronic Urticaria

Journal of Allergy and Clinical Immunology 2026 Open access

Read full text

Authors: Sravan Jaggumantri, Martin Metz, Edwin Tucker, Patricia Carlos, Shirley Dehn, Wendy W. Pang, Daniel C. Adelman, Tomasz Hawro

DOI: 10.1016/j.jaci.2025.12.079

Cited by: 0

Fields of Study & Subjects

Urticaria and Related Conditions Mast cells and histamine Eosinophilic Disorders and Syndromes